Home siRNA SR301762
GCK (ID 2645) Trilencer-27 Human siRNA
- GCK (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 2645)
- Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol
- Included - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml
- SiTran1.0: Transfection reagent designed for RNAi duplex (0.5 ml)
* These siRNA duplexes were designed to be effective against all transcriptional variants at this gene locus.
** Delivery time is an estimate in business days. Occasional delays may occur due to unforeseen complexities in the preparation of your construct. International customers may expect an additional 1-2 weeks in shipping
Also for GCK (Locus ID 2645)
|Amount: 2 nmol each, lyophilized||Purity: HPLC purified|
|Quality Control: Tested by ESI-MS||Sequences: Available with shipment|
|Stability: One year from date of shipment when stored at -20ºC||Shipment: Ambient|
|# of transfections: Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM)|
|Note: Single siRNA duplex (10nmol) can be ordered. See details at http://www.origene.com/siRNA/|
|Synonyms: HXKP;GK; GLK; HHF3; HK4; HKIV; MODY2; ATP:D-hexose 6-phosphotransferase; OTTHUMP00000024521; OTTHUMP00000159308; glucokinase; hexokinase D, pancreatic isozyme; glucokinase (hexokinase 4)|
|Summary: Hexokinases phosphorylate glucose to produce glucose-6-phosphate, the first step in most glucose metabolism pathways. Alternative splicing of this gene results in three tissue-specific forms of glucokinase, one found in pancreatic islet beta cells and two found in liver. The protein localizes to the outer membrane of mitochondria. In contrast to other forms of hexokinase, this enzyme is not inhibited by its product glucose-6-phosphate but remains active while glucose is abundant. Mutations in this gene have been associated with non-insulin dependent diabetes mellitus (NIDDM), maturity onset diabetes of the young, type 2 (MODY2) and persistent hyperinsulinemic hypoglycemia of infancy (PHHI). [provided by RefSeq, Apr 2009]. |Performance Guranteed:
OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.
For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at email@example.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).